These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 2057989)
21. 6-mercaptopurine plasma levels in children with acute lymphoblastic leukemia: relation to relapse risk and myelotoxicity. Hayder S; Lafolie P; Björk O; Peterson C Ther Drug Monit; 1989 Nov; 11(6):617-22. PubMed ID: 2595740 [TBL] [Abstract][Full Text] [Related]
22. Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy? Balis FM; Jeffries SL; Lange B; Murphy RF; Doherty KM; Arndt CA; Luery N; Poplack DG Am J Pediatr Hematol Oncol; 1989; 11(3):324-6. PubMed ID: 2782561 [TBL] [Abstract][Full Text] [Related]
23. Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia. Zou Y; Mei D; Yuan J; Han J; Xu J; Sun N; He H; Yang C; Zhao L Int J Nanomedicine; 2021; 16():1127-1141. PubMed ID: 33603372 [TBL] [Abstract][Full Text] [Related]
24. Extremely low dose of 6-mercaptopurine in a Chinese child with acute lymphoblastic leukaemia and multiple pharmacogenetic mutations. Zhai XY; Zhou Y; Dong L; Nie AQ; Zhi LJ; Jacqz-Aigrain E; Wang TY; Wang L; Zhao W J Clin Pharm Ther; 2021 Feb; 46(1):74-77. PubMed ID: 32893890 [TBL] [Abstract][Full Text] [Related]
25. Cranial irradiation and cerebrospinal fluid levels of 6-mercaptopurine in children with acute leukemia. Riccardi R; Lasorella A; Tartaglia RL; Riccardi A; Servidei T; Mastrangelo R Med Oncol Tumor Pharmacother; 1991; 8(2):95-8. PubMed ID: 1749306 [TBL] [Abstract][Full Text] [Related]
26. A phase II trial of continuous-infusion 6-mercaptopurine for childhood leukemia. Adamson PC; Zimm S; Ragab AH; Balis F; Steinberg SM; Kamen BA; Vietti TJ; Gillespie A; Poplack DG Cancer Chemother Pharmacol; 1992; 30(2):155-7. PubMed ID: 1600597 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of mercaptopurine: plasma drug and red cell metabolite concentrations after an oral dose. Welch J; Lennard L; Morton GC; Lilleyman JS Ther Drug Monit; 1997 Aug; 19(4):382-5. PubMed ID: 9263376 [TBL] [Abstract][Full Text] [Related]
29. Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Lennard L; Davies HA; Lilleyman JS Br J Cancer; 1993 Jul; 68(1):186-90. PubMed ID: 8318412 [TBL] [Abstract][Full Text] [Related]
30. Why more 6-mercaptopurine? Kamen BA Semin Hematol; 1991 Jul; 28(3 Suppl 4):12-4. PubMed ID: 1780746 [No Abstract] [Full Text] [Related]
31. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lennard L; Lilleyman JS; Van Loon J; Weinshilboum RM Lancet; 1990 Jul; 336(8709):225-9. PubMed ID: 1973780 [TBL] [Abstract][Full Text] [Related]
32. Compliance with oral chemotherapy in childhood lymphoblastic leukaemia. Davies HA; Lilleyman JS Cancer Treat Rev; 1995 Mar; 21(2):93-103. PubMed ID: 7758006 [No Abstract] [Full Text] [Related]
33. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. Relling MV; Hancock ML; Rivera GK; Sandlund JT; Ribeiro RC; Krynetski EY; Pui CH; Evans WE J Natl Cancer Inst; 1999 Dec; 91(23):2001-8. PubMed ID: 10580024 [TBL] [Abstract][Full Text] [Related]
34. 'Acceptability' of a new oral suspension formulation of mercaptopurine in children with acute lymphoblastic leukaemia. Mulla H; Buck H; Price L; Parry A; Bell G; Skinner R J Oncol Pharm Pract; 2016 Jun; 22(3):387-95. PubMed ID: 25837624 [TBL] [Abstract][Full Text] [Related]
35. Large interindividual variations in the pharmacokinetics of oral 6-mercaptopurine in maintenance therapy of children with acute leukaemia and non-Hodgkin lymphoma. Lafolie P; Hayder S; Björk O; Ahström L; Liliemark J; Peterson C Acta Paediatr Scand; 1986 Sep; 75(5):797-803. PubMed ID: 3564948 [TBL] [Abstract][Full Text] [Related]
36. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lilleyman JS; Lennard L Lancet; 1994 May; 343(8907):1188-90. PubMed ID: 7909868 [TBL] [Abstract][Full Text] [Related]
37. Effect of chemotherapy on the energy and protein metabolism of children near the end of treatment for acute lymphoblastic leukemia. Vaisman N; Stallings VA; Chan H; Weitzman SS; Clarke R; Pencharz PB Am J Clin Nutr; 1993 May; 57(5):679-84. PubMed ID: 8480686 [TBL] [Abstract][Full Text] [Related]
38. Effect of a Daily Text Messaging and Directly Supervised Therapy Intervention on Oral Mercaptopurine Adherence in Children With Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. Bhatia S; Hageman L; Chen Y; Wong FL; McQuaid EL; Duncan C; Mascarenhas L; Freyer D; Mba N; Aristizabal P; Walterhouse D; Lew G; Kempert PH; Russell TB; McNall-Knapp RY; Jacobs S; Dang H; Raetz E; Relling MV; Landier W JAMA Netw Open; 2020 Aug; 3(8):e2014205. PubMed ID: 32852553 [TBL] [Abstract][Full Text] [Related]
39. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group). Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM; Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274 [TBL] [Abstract][Full Text] [Related]
40. Individualized 6-mercaptopurine increments in consolidation treatment of childhood acute lymphoblastic leukemia: A NOPHO randomized controlled trial. Tulstrup M; Frandsen TL; Abrahamsson J; Lund B; Vettenranta K; Jonsson OG; Marquart HVH; Albertsen BK; Heyman M; Schmiegelow K Eur J Haematol; 2018 Jan; 100(1):53-60. PubMed ID: 28983968 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]